
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
The multi-year strategic agreement between Bristol-Myers Squibb and Concerto HealthAI announced will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials for precision treatment and improved patient outcomes.
Read the full release






